Study Report on Retrospective Clinical Follow-up of Post Exposure Prophylaxis with Inj. Anti Rabies Vaccine (ARV) or Inj. Anti Rabies Vaccine (ARV) + Inj. Rabies Immunoglobulin (RIG) in Animal Bite Patients Attending at BITID
Keywords:Animal-bites, Rabies, BITID, ARV, RIG
Rabies is a universally fatal and equally preventable zoonotic disease that is prevalent in Bangladesh. Bangladesh Institute of Tropical & Infectious Diseases (BITID) is the national institute for tropical-infectious diseases in the country which is working as a center for rabies control under the Rabies Elimination Program of the Centers for Disease Control and Prevention (CDC). This report is about the cumulative follow-up of patients inflicted with animal bites who had attended the institute during the period of September 2014 to December 2015. The characteristics of animal bites and subsequent clinical outcome of the post-exposure prophylaxis with ARV and/or RIG in the prevention of Rabies was recorded. About 1398 patients were analyzed in two groups, Group A comprised of 886 patients receiving Inj ARV only and Group B included 512 patients who received both of Inj ARV and RIG. Among the analyzed patients, Category lll bites were more prevalent at 54.7%. The total of 84% of the patients who attended for rabies PEP completed the vaccination schedule. Most of the CAT- III patients attended the institute within 2 days of the animal bites. No patients had any adverse effect following vaccination or RIG and none had developed Rabies.
Health Bulletin, 2015.Goverment of the people’s Republic of Bangladesh, Ministry of health and family welfare.
WHO. WHO expert consultation on Rabies. First report. WHO technical report series. 2004; 931:1-121.
World Health Organization. Expert consultation on Rabies, Technical report series 931, Geneva, Switzerland, 2005.
Dutta JK. Adverse reactions to purified chick embryo cell rabies vaccine. Vaccine 1994;12:1484
How to Cite
ABC Research Alert is an Open Access journal. Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a CC BY-NC 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of their work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal. We require authors to inform us of any instances of re-publication.